About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Is There a Role for IO in EGFR+ Metastatic Lung Cancer?
By
GRACE
FEATURING
Helena Yu
By
GRACE
FEATURING
Helena Yu
4,767 views
August 2, 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
18:47
Total Health
Updates in the Management of NSCLC: Systemic Therapy Year in Review
Feat.
W. Iams
35:40
Balazs Halmos
Year in Review: Lung Cancer
11:07
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…
Feat.
J. West
17:20
Total Health
2024 Intervention Selection & Sequencing in Early Stage NSCLC
Feat.
J. Porter
08:49
David Carbone
The Use of IO Doublet in PD-L1-Negative NSCLC
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage
Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …
Feat.
E. Rodriguez
07:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…
Feat.
J. West
26:21
Memorial Sloan Kettering Cancer Center
NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…
Feat.
M. Hwang
14:49
Vivek Subbiah
Year in Review: Precision Medicine
16:12
Total Health
2024 Updates on the Fast-Changing NSCLC Landscape
Feat.
R. Osarogiagbon
23:32
2023 West Oncology Conference
2023 Updates on Neoadjuvant and Adjuvant NSCLC
Feat.
M. Johnson
17:34
ecancer
Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…
Feat.
L. Raez
11:50
GRACE
The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies
Feat.
J. Rotow
20:27
Yale Cancer Center
Progress in the Treatment of NSCLC
Feat.
R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting
PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…
Feat.
N. Girard
54:26
Yale Cancer Center
Year in Review: Progress in NSCLC Treatment
Feat.
R. Herbst
23:36
CHEST 2022 Coverage
Immune Checkpoint Inhibitor Pneumonitis in Lung Cancer
Feat.
J. Possick
26:42
Total Health
ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…
Feat.
J. Bauman
17:57
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…
Feat.
D. Carbone,
B. Stiles
08:05
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvan…
Feat.
M. Johnson
